Systematic review with meta‐analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|41|7|603-612

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.41, Iss.7, 2015-04, pp. : 603-612

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pericarditis during infliximab therapy in paediatric ulcerative colitis

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 43, Iss. 1, 2018-02 ,pp. : 107-109

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 5, 2010-05 ,pp. : 886-891

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systematic review with network meta‐analysis: comparative assessment of tofacitinib and biological therapies for moderate‐to‐severe ulcerative colitis

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 454-465

John Wiley & Sons Inc

Access to resources Recommend Favorite

Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 1, 2018-01 ,pp. : 226-231

John Wiley & Sons Inc

Access to resources Recommend Favorite

Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 478-484

John Wiley & Sons Inc

Access to resources Recommend Favorite